Shopping Cart
- Remove All
Your shopping cart is currently empty
DN-108, a thiazolidinedione derivative, acts as an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic properties. It improves hyperglycemia, hypertriglyceridemia, and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increases 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity, making it a promising candidate for type 2 diabetes research.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks |
| Description | DN-108, a thiazolidinedione derivative, acts as an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic properties. It improves hyperglycemia, hypertriglyceridemia, and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increases 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity, making it a promising candidate for type 2 diabetes research. |
| Molecular Weight | 366.43 |
| Formula | C20H18N2O3S |
| Cas No. | 195604-21-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.